

Product Information

Tafamidis, Purity $\geq 98\%$

Cat. No.: X24-09-YM1282

Size: 5 mg; 10 mg; 20 mg; 50 mg


MDL: MFCD16621109

CAS Number: 594839-88-0

Compound CID: 11001318

Synonym: 594839-88-0; Vyndamax; FX-1006;

2-(3,5-Dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid



This product is for research use only and is not intended for diagnostic use.

Product Information

Description	Tafamidis, soluble in DMSO and insoluble in water and ethanol, is a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. The molecular weight of the compound is 308.12, and its molecular formula is C ₁₄ H ₇ Cl ₂ NO ₃ .
Molecular Weight	308.12
Molecular Formula	C ₁₄ H ₇ Cl ₂ NO ₃
IUPAC Name	2-(3,5-Dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid
InChI	InChI=1S/C14H7Cl2NO3/c15-9-3-8(4-10(16)6-9)13-17-11-2-1-7(14(18)19)5-12(11)20-13/h1-6H,(H,18,19)
InChI Key	TXEIIIPDJKFWEEC-UHFFFAOYSA-N
Canonical SMILES	C1=CC2=C(C=C1C(=O)O)OC(=N2)C3=CC(=CC(=C3)Cl)Cl
Form	Lyophilized powder
Purity	$\geq 98\%$
Impurities	Free from inappropriate visible particulates, foreign matter, discoloration, or other defects.
Solubility	<i>In vitro</i> : DMSO: 30 mg/mL (97.36 mM); Water: insoluble; Ethanol: insoluble
Identity	Confirmed by NMR/HPLC/MS.
Stability	In its lyophilized form, the chemical remains stable for 36 months.
Quality Level	Research grade
Applications	Tafamidis can be studied extensively for its potential therapeutic applications in the treatment of transthyretin amyloidosis (ATTR), a condition characterized by the accumulation of misfolded proteins, leading to organ dysfunction, particularly affecting the heart and nervous system.



Storage

Store at -20°C, and keep desiccated.
